Patients in a Phase 3 study for retatrutide lost an average of 49.6 pounds over 80 weeks using a 12 mg dose. Eli Lilly reported the clinical results for its next-generation obesity treatment, noting that the medication also reduced A1C levels among participants.

The company will submit a biologics license application for retatrutide to the Food and Drug Administration in the first quarter of 2027.